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Abstract
Background—Inherited susceptibility genes have been associated with histopathologic 
characteristics of tumors.
Objective—To identify associations between histology of melanomas and CDKN2A genotype.
Methods—Case-control study design comparing 28 histopathologic tumor features among 
individuals with sporadic melanomas (N=81) and cases from melanoma families with (N=123) 
and without (N=120) CDKN2A germline mutations.
Results—Compared with CDKN2A-negative cases, mutation carriers tended to have histologic 
features of superficial spreading melanoma subtype including higher pigmentation (ptrend=0.02) 
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and increased pagetoid scatter (ptrend=0.07) after adjusting for age at diagnosis, sex, and AJCC 
thickness category. Similar associations were observed when comparing mutation carriers to a 
combined group of CDKN2A-negative (wild type) and sporadic melanomas. The presence of 
spindle cell morphology in the vertical growth phase was also an important predictor of genotype. 
Of the fifteen cases with this phenotype, none were observed to harbor a CDKN2A mutation.
Limitations—Our study examined rare mutations and may have been underpowered to detect 
small, but biologically significant associations between histology and genotype.
Conclusion—Familial melanomas with CDKN2A mutations preferentially express a histologic 
phenotype of dense pigmentation, high pagetoid scatter, and a non-spindle cell morphology in the 
vertical growth phase.
Keywords
Familial melanoma; sporadic melanoma; CDKN2A; histology; Classification and Regression Tree 
(CART) analysis; pigmentation; pagetoid scatter; genetic testing
Introduction
Melanoma clusters within families in about 5-10% of cases, and CDKN2A germline 
mutations are found in 20-40% of familial melanoma kindreds.1 In contrast, the prevalence 
of a CDKN2A germline mutation in sporadic melanomas is low ranging from 0.2-2.0%.2-5 
The CDKN2A locus codes for two proteins, p16INK4 and p14ARF, that function as tumor 
suppressors in the Rb/E2F and HDM2/p53 pathways respectively.6,7 Previous research has 
shown that specific histopathologic features are associated with inherited genetics. Female 
BRCA1 and BRCA2 carriers are predisposed to medullary and lobular carcinomas of the 
breast, respectively; and the 6q22.2 and 6p21.32 genetic regions are associated with 
adenocarcinomas of the lung.8-12
To date, there has been limited information published as to the clinicopathologic subtypes of 
melanoma most likely to occur in familial melanoma kindreds, which are defined by the 
presence of 2 or more melanomas amongst first-degree relatives or 3 or more melanomas 
irrespective of degree of relationship.5 Previous descriptive series have reported an 
overrepresentation of superficial spreading morphology among familial melanomas, but 
these studies were relatively small in size and did not report whether specific histologic 
features were associated with genotype.13,14-16 Bastian and colleagues recently reported 
good correlation between melanoma histology and somatic mutation status of the oncogenes 
BRAF and NRAS, whose profiles broadly resembled those of superficial spreading and 
lentigo maligna type melanomas, respectively.17 Amongst melanomas arising in individuals 
with CDKN2A germline mutations, the prevalence of NRAS and BRAF mutations is 16% and 
37%, respectively.16
The purpose of this study was to determine if histologic features of melanoma are associated 
with inherited CDKN2A mutations, which are the most prevalent genetic alterations 
observed in melanoma families. We hypothesized that the majority of the melanomas 
diagnosed in CDKN2A mutation carriers would be melanomas of the superficial spreading 
subtype, and that histological markers of this tumor subtype would be observed at higher 
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proportions in this group. This hypothesis is based on our experience and that of others that 




We performed a case-control study of the histopathologic features of familial melanomas 
from family members with (N=123) and without (N=120) CDKN2A germline mutations and 
sporadic melanomas (N=81). Hereinafter, melanomas from family members who carry a 
CDKN2A mutation are referred to as “CDKN2A-positive” and those from family members 
testing negative for a CDKN2A mutation are referred to as “CDKN2A-negative”. Familial 
melanoma cases were obtained from individuals in families with 2 first-degree relatives 
diagnosed with melanoma or families with 3 or more cases of melanoma irrespective of 
degree of relationship.5 Tumor samples were collected from Philadelphia, PA and Bethesda, 
MD (USA), Barcelona (Spain), Brisbane and Sydney (Australia), Genoa (Italy), Leeds 
(United Kingdom), and Leiden (Netherlands) for use in this Melanoma Genetics Consortium 
(GenoMEL, www.genomel.org) study. All melanoma specimens were fixed in formalin, 
stored in paraffin blocks, and slides were subsequently cut for pathologic review. For each 
melanoma family, only one case was selected for use in this study. All slides were stripped 
of patient identifiers to protect patient privacy. GenoMEL centers contributing tumor slides 
were asked to match sporadic and familial CDKN2A-negative melanomas to familial 
CDKN2A-positive melanomas on age at diagnosis, sex, and American Joint Committee on 
Cancer (AJCC) thickness categories to the best of their abilities. In practice however, 
matching was inconsistently applied across centers. This resulted in a collection of tumor 
slides that ranged from those selected without regard to any matching criteria to those 
matched to varying degrees dependent upon the number of familial melanoma specimens 
and/or availability of sporadic melanoma cases at a given center. The distribution of age at 
diagnosis, sex, and AJCC thickness category across the three comparison groups is 
presented in Supplementary Table 1.
Pathology Review
All melanomas were independently reviewed by DEE and MRS, who were blinded to all 
patient and tumor characteristics including research group of origin and mutation status. 
Radial growth phase (RGP), vertical growth phase (VGP), and stromal histological features 
were recorded for each tumor. Grading of many of the features (listed and further discussed 
below) was based on the system developed and validated by Bastian’s group.17,19 
Disagreements regarding histologic features were resolved by consensus after joint review 
of the case.
Description of Histopathologic Features
Melanoma Subtype—Melanoma cases were classified as superficial spreading melanoma 
(SSM), lentigo maligna melanoma (LMM), acral melanoma (AM), mucosal lentiginous 
melanoma (MLM), invasive melanoma with regressed RGP, or nodular melanoma (no RGP) 
subtype according to the World Health Organization (WHO) classification scheme and other 
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literature.20-22 Definitions of radial and vertical growth phase were adopted from previously 
published works.20,23-25
Pigment grade—Pigment grade was based on a 0-3 scale.17 In tumors with heterogeneous 
pigmentation, the pigment grade was based upon the area of most intense pigmentation. 
Grade 0 was assigned to amelanotic tumors. Grade 1 was assigned to tumors with faint 
pigmentation at low power (100X). Grade 2 was assigned to tumors with moderate 
pigmentation at low power but translucent cytoplasm. Grade 3 was assigned to tumors with 
high pigmentation at low power roughly equal to that of the nucleus.
Epidermal (Pagetoid) Scatter—Pagetoid scatter was graded on a 0-3 scale. Grade 0 was 
assigned to tumors with no pagetoid scatter. Grades 1 (“low”), 2 (“moderate”), and 3 (“high) 
were assigned to tumors in which 1-25%, 26-50%, and greater than 50% of the epidermal 
melanoma cells were above the basal layer of the epidermis, respectively.17
Nesting Grade—Nesting was defined as a clustering of five or more cells within the 
epidermis and was graded on a 0-3 scale. Grade 0 was assigned to tumors in which there 
was no nesting of melanoma cells within the epidermis. Grades 1 (“mild”), 2 (“moderate”), 
and 3 (“high”) were assigned to tumors in which 1-25%, 26-50%, and greater than 50% of 
the epidermal melanoma cells were located within nests, respectively.17
RGP and VGP Cytologic Grade—Low grade was used to describe tumor cells with 
nuclei similar in size to basal keratinocytes, regular shape, and no nucleoli. Intermediate 
grade was used to describe tumor cells with enlarged and slightly irregular nuclei, 
moderately clumped chromatin, hyperchromasia, and small or absent nucleoli. High grade 
was used to describe tumor cells with markedly pleomorphic and hyperchromatic irregular 
nuclei, and large eosinophilic or amphophilic nucleoli.
VGP Cell Type—Cells were classified as epithelioid, spindle, nevoid, or spitzoid. The 
ratio of the long to short axis for epithelioid and spindle classification was 1:1 and >2:1 
respectively. Cells were classified as nevoid if they resembled those of a banal nevus. 
Spitzoid classification was assigned to tumors with very large plump spindle cells with 
abundant cytoplasm, large amphophilic nucleoli, and open chromatin.
Tumor Infiltrating Lymphocytes—Tumor infiltrating lymphocytes (TILs) were defined 
as lymphocytes in contact with melanoma cells in the dermis. TILs were graded on a 0-3 
scale. Grade 0 was assigned to tumors with no TILs. Grades 1 (“low”), 2 (“medium”), and 3 
(“high”) were assigned to tumors in which 1-25%, 26-50%, and greater than 50% of dermal 
melanoma cells were in contact with lymphocytes, respectively.
Fibroplasia—Concentric and diffuse fibroplasia, as defined by Clark et al, were graded 
using a 0-2 scale.26 Grade 0 was assigned to tumors with no fibroplasia. Grade 1 (“slight”) 
was assigned to tumors with 1-25% of the epidermal tumor breadth demonstrating 
fibroplasia. Grade 2 (“definite”) was assigned to tumors with >25% of the epidermal tumor 
breadth demonstrating fibroplasia.26
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Perivascular and Diffuse Lymphocytes—Perivascular and diffuse lymphocytes were 
each graded on a 0-3 scale. Grade 0 was assigned to tumors with no lymphocytic infiltrate. 
Grade 1 (“low”) was assigned to tumors with scattered lymphocytes in the tumor bed or 
around blood vessels. Grade 2 (“medium”) was assigned to tumors with a lymphocyte to 
melanoma cell ratio of 5:1 in the tumor bed or 1-2 concentric layers of lymphocytes around 
blood vessels. Grade 3 (“high”) was assigned to tumors with a lymphocyte to melanoma cell 
ratio of >10:1 in the tumor bed or >2 concentric layers of lymphocytes around blood vessels.
Actinic (Solar) Elastosis—Actinic Elastosis was graded on a 1-3 scale. Grade 1 (“mild”) 
was assigned to tumors with a background of scattered elastotic fibers lying as individual 
units between collagen bundles. Grade 2 (“moderate”) was assigned to tumors with a 
background of densely scattered elastotic fibers distributed predominantly as bushels. Grade 
3 (“severe”) was assigned to tumors with a background of amorphous deposits of blue-gray 
material with loss of fiber texture.17,19
Statistical Analysis
Using logistic regression, odds ratios (OR) and corresponding 95% confidence intervals (CI) 
were estimated for associations between groups defined by CDKN2A status (CDKN2A-
positive versus CDKN2A-negative; CDKN2A-postive versus sporadic; CDKN2A-positive 
versus combined CDKN2A-negative and sporadic) and measured RGP, VGP, and stromal 
histologic features after adjusting for age at diagnosis, sex, and AJCC tumor thickness. 
Overall differences in the prevalence of histological variables were determined by chi-
square analysis for nominal categorical variables or Mantel-Haenszel (M-H) test for trend 
for ordinal categorical variables. All histologic variables with a p < 0.20 were subsequently 
included in a forward selection multivariate logistic regression model to determine 
independent associations with mutation status, and these models were again adjusted for age 
at diagnosis, sex, and AJCC tumor thickness. We excluded melanoma subtype from the 
multivariate analysis because it is a morphologic classification scheme based upon the 
presence of specific histologic features and hence was highly collinear with the same 
features as variables incorporated into the multivariate models. Sporadic cases were 
combined with CDKN2A-negative familial cases for the third analysis because of their low 
prevalence for mutations at the CDKN2A locus.3 All statistical analyses were performed 
using STATA v12.1 (StataCorp LP, College Station, TX) software.
Classification and Regression Tree (CART) Analysis
Classification and regression tree (CART) analysis was performed to evaluate the ability of 
histopathologic features to predict CDKN2A genotype. CART analysis creates binary nodes 
with the objective of minimizing within-group heterogeneity at each branch point. 27,28 We 
used the computer software package, Salford Predictive Modeler (Salford Systems, San 
Diego, California), to perform each CART analysis. Each terminal node (branch point) has 
listed the estimated probability (%) with 95% confidence limits of a CDKN2A mutation.
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Twenty-eight histopathologic features were recorded for 324 familial or sporadic melanoma 
cases, and comparisons among groups are reported in Table 1. Associations between 
histology and genotype were similar when analyzing invasive and melanoma in situ cases 
separately (Supplementary Tables 2 and 3).
Familial Melanoma: CDKN2A-Positive vs. CDKN2A-Negative Cases
Compared with CDKN2A-negative cases, mutation carriers tended to have histologic 
features of superficial spreading melanoma subtype including higher pigmentation 
(ptrend=0.02) and increased pagetoid scatter (ptrend=0.07) after adjusting for age at diagnosis, 
sex, and AJCC thickness category. In multivariable models, higher pagetoid scatter 
(ptrend=0.01) and increased density of TILs (ptrend=0.02) were also associated with CDKN2A 
mutations after adjusting for age at diagnosis, sex, AJCC thickness category, pigmentation, 
associated junctional nevi, RGP cytologic grade, diffuse fibroplasia, VGP cell type, VGP 
cytologic grade, and VGP mitotic rate. Differences in VGP cell type (p=0.002) were also 
observed between the two groups.
CDKN2A-Positive vs. Sporadic Melanomas
Familial melanomas with CDKN2A mutations had a lower VGP cytologic grade 
(ptrend=0.04) and were more likely to have a non-mitogenic VGP (p<0.001) compared to 
sporadic cases after adjusting for age at diagnosis, sex, and AJCC thickness category. In 
multivariable models, these associations did not achieve statistical significance after 
additional adjustment for age at diagnosis, sex, AJCC thickness category, pigmentation, 
RGP mitotic rate, RGP breadth, associated junctional nevi, and VGP cell type. Differences 
in VGP cell type (p=0.01) were also observed between the two case groups.
CDKN2A-Positive vs. Combined CDKN2A-negative and Sporadic Cases
Compared to a combined group of CDKN2A-negative familial and sporadic cases, CDKN2A 
mutation carriers were more likely to have higher pigmentation (ptrend=0.04), lower VGP 
cytologic grade (ptrend=0.03), and a non-mitogenic VGP (p<0.001) after adjusting for age at 
diagnosis, sex, and AJCC thickness category. These associations were not observed in the 
multivariable logistic regression model, which adjusted for age at diagnosis, sex, AJCC 
thickness category, pagetoid scatter, RGP breadth, RGP cytologic grade, RGP mitotic rate, 
associated junctional nevi, diffuse fibroplasia, and VGP cell type. Differences in VGP cell 
type (p=0.01) were also observed between the mutation carriers and the combined group of 
CDKN2A-negative and sporadic cases. VGP spindle cell morphology was exclusively seen 
within the CDKN2A-negative (N=9) and sporadic (N=6) groups.
Classification and Regression Tree (CART) Analysis
CART analysis revealed that many of the histological variables that were associated with 
genotype in the logistic regression analysis were also predictive of mutation status. Amongst 
familial melanomas, pigmentation, VGP cell type, and TILs were important predictors of 
CDKN2A genotype (Figure 1). When comparing mutation carriers to sporadic cases, VGP 
mitoses was a strong predictor of mutation status (Figure 2). Similar findings from these two 
Sargen et al. Page 6






















analyses were observed when comparing the histologic features of mutation carriers to the 
combined control group of CDKN2A-negative familial and sporadic cases (Figure 3).
Discussion
Consistent with our study hypothesis, we found that histologic features of SSM 
classification, including increased pigmentation and increased pagetoid scatter, were more 
common among familial melanoma cases with CDKN2A mutations compared to familial 
cases who were CDKN2A-negative.
Pigmentation in melanocytes is regulated by microphthalmia-associated transcription factor 
(MITF). MITF upregulates expression of tyrosinase in melanocytes resulting in increased 
synthesis of the pigment melanin.29 MITF plays an important role in cell cycle regulation by 
binding to the p16 (CDKN2A locus) promoter site where it induces gene transcription.30 
There is a negative feedback interaction between MITF and p16 whereby inactivation of the 
latter is associated with MITF amplification.31 Therefore, the high pigmentation observed in 
CDKN2A mutation melanoma cases may reflect the loss of p16 negative feedback on the 
pigmentation regulator MITF.
Higher scatter grade was also associated with the presence of a CDKN2A mutation among 
familial melanomas after adjusting for potential confounders in our multivariate analysis, 
and this association trended towards statistical significance when mutation carriers were 
compared to the combined group of familial CDKN2A-negative and sporadic cases. Pagetoid 
scatter is a well-characterized feature of SSM, also referred to as pagetoid melanoma in the 
literature, and this association supports our original hypothesis.17,19 VGP cell type was also 
an important predictor of mutation status. Of the fifteen cases with VGP spindle cell 
morphology, none were CDKN2A mutation carriers. Spindle cells are more characteristically 
seen in lentigo maligna type melanomas rather than superficial spreading melanomas. It was 
also observed amongst familial cases that melanomas harboring a CDKN2A mutation had an 
increased density of TILs after adjusting for potential confounders. This observation might 
suggest that the presence of a CDKN2A mutation confers a phenotype of increased immune 
surveillance accompanying the individual’s predisposition for cancer, or perhaps that 
CDKN2A-mutated melanomas are more immunogenic.
Models comparing mutation positive to sporadic melanoma cases showed that melanomas 
harboring a CDKN2A mutation were more likely to have a lower VGP cytologic grade and 
to have a non-mitogenic VGP after adjusting for age at diagnosis, sex and AJCC thickness 
category. These associations are likely attributable to more frequent surveillance for 
melanoma within melanoma families.
To our knowledge, our study is the largest to date comparing the histologic features of 
sporadic melanomas and familial melanomas with and without CDKN2A germline 
mutations. A limitation of our study is that our analysis may have been underpowered to 
detect certain biologically important associations between histology and CDKN2A genotype.
In conclusion, our study demonstrates that histologic features of SSM are associated with 
the presence of a CDKN2A mutation. If these findings are validated, clinicians can use 
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histology in conjunction with clinical information to help determine which patients should 
be offered CDKN2A genetic testing.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• It is unknown whether CDKN2A mutations are associated with specific 
histopathological features of melanomas arising within melanoma families.
• Familial melanomas with CDKN2A mutations preferentially express a non-
spindle cell morphology, dense pigmentation, and high pagetoid scatter.
• If these findings are validated, clinicians can use histology to help determine 
which patients should be offered CDKN2A genetic testing.
Sargen et al. Page 11























Classification and Regression Tree (CART) for familial melanomas with (N=123) and 
without (N=120) CDKN2A mutations. The probability (%) of a CDKN2A mutation, its 95% 
confidence limits, and the number of cases for each terminal node are reported in the table 
beneath the figure.
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Classification and Regression Tree (CART) comparing familial melanomas with CDKN2A 
mutations (N=123) to sporadic melanomas (N=81). The probability (%) of a CDKN2A 
mutation, its 95% confidence limits, and the number of cases for each terminal node are 
reported in the table beneath the figure.
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Classification and Regression Tree (CART) comparing familial melanomas with CDKN2A 
mutations (N=123) to a combined group of familial melanomas without CDKN2A mutations 
(N=120) and sporadic melanomas (N=81). The probability (%) of a CDKN2A mutation, its 
95% confidence limits, and the number of cases for each terminal node are reported in the 
table beneath the figure.
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